{"id":"W4213440518","doi":"10.1016/j.ejca.2022.01.017","title":"Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Moderna; Genentech; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hazard ratio; Placebo; Internal medicine; Confidence interval; Proportional hazards model; Melanoma; Oncology; Gastroenterology; Surgery; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002515488,0.0001871758,0.0006899395,0.0004067934,0.00008089982,0.00001309055,0.0003000257,0.00002959956,0.0001562395],"category_scores_gemma":[0.0006667553,0.0001411342,0.0001491598,0.000474235,0.0002177885,0.00009425623,0.00007941641,0.0007937978,3.135953e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002283105,"about_ca_system_score_gemma":0.0006743033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005533759,"about_ca_topic_score_gemma":0.00007846892,"domain_scores_codex":[0.9956121,0.002148685,0.001006135,0.0001984456,0.0007712024,0.0002633752],"domain_scores_gemma":[0.9978003,0.0006616729,0.001001334,0.0002802232,0.0001651165,0.00009137591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.969317,0.0007754737,0.004972328,0.00008474638,0.0003340532,0.001108453,0.008532136,0.001411393,0.001078697,0.00002129055,0.001393033,0.01097139],"study_design_scores_gemma":[0.781309,0.03569042,0.1509763,0.0008006252,0.0009044617,0.0002985036,0.009782987,0.0008465972,0.00159398,0.00001206614,0.01750252,0.0002825205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925806,0.004777094,0.00001504045,0.0006010219,0.0005328403,0.000867397,0.00009006348,0.00000574824,0.0005301761],"genre_scores_gemma":[0.9973887,0.001810513,0.0000351303,0.00004851296,0.00046719,0.00002373244,0.000006814538,0.0000353432,0.000184114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.188008,"threshold_uncertainty_score":0.5755286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01622387118143329,"score_gpt":0.2903398586936221,"score_spread":0.2741159875121887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}